Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients.

Thrombosis and haemostasis - 1 Aug 2009

Palareti Gualtiero, Cosmi Benilde

Abstract excerpt

Anticoagulation with vitamin K antagonists (VKAs) has been shown to be effective in the prevention and treatment of thrombotic complications in various clinical settings, including atrial fibrillation (AF), venous thromboembolism (VTE), acute coronary syndromes and after invasive cardiac procedures. Bleeding is the most important complication of VKAs and a major concern for both physicians and patients. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Cytochrome P-450 CYP2C9
Share to Drug Interactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hemorrhage

Share to International Normalized Ratio

Share to Vitamin K

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Identifiers

PMID: 19652877
DOI: 10.1160/TH08-11-0730

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients.PMID 19652877Read ↗

Safety profile of rivaroxaban in first-time users treated for venous thromboembolism (deep vein thrombosis and pulmonary embolism) in four European countriesSemantic proximity Read ↗

Gastrointestinal Bleeding During Direct Oral Anticoagulants Therapy in Patients With Nonvalvular Atrial Fibrillation and Risk of PolypharmacySemantic proximity Read ↗

An ADR pharmaceutical care for severe gastrointestinal bleeding of rivaroxaban in a patient with non-valvular atrial fibrillation based on TDM and genetic testingSemantic proximity Read ↗

Anticoagulation Therapy for Venous Thromboembolism From Vitamin K Antagonists to Direct Oral Anticoagulants and BeyondSemantic proximity Read ↗

Risk Factors for Rivaroxaban-Related Bleeding Events—Possible Role of Pharmacogenetics: Case SeriesSemantic proximity Read ↗

North American Thrombosis Forum, AF Action Initiative Consensus Document.Semantic proximity Read ↗

Bleeding in cardiac patients prescribed antithrombotic drugs: Electronic health record phenotyping algorithms, incidence, trends and prognosisSemantic proximity Read ↗

Bleeders, bleeding rates, and bleeding score.Semantic proximity Read ↗

Risk factors associated with a thrombotic or bleeding event in patients treated with vitamin K antagonists.Semantic proximity Read ↗

Direct Oral Anticoagulants in Patients with Thrombophilia: Challenges in Diagnostic Evaluation and Treatment.Semantic proximity Read ↗

Bleeding Events Associated with Rivaroxaban Therapy in Naive Patients with Nonvalvular Atrial Fibrillation: A Longitudinal Study from a Genetic Perspective with INR Follow-Up.Semantic proximity Read ↗

The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.